UCSF Benioff Children's Hospital Oakland-
Welcome,         Profile    Billing    Logout  
 7 Trials 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Agrawal, Anurag
NCT05489887: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Recruiting
2
76
Canada, US
Naxitamab, Danyelza, Ceritinib
Giselle Sholler, Y-mAbs
High-risk Neuroblastoma
09/26
09/33
NMTT, NCT02679144: Neuroblastoma Maintenance Therapy Trial

Recruiting
2
441
Canada, US
Difluoromethylornithine (DFMO), eflornithine
Giselle Sholler, Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
02/28
02/33
NCT04696029: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Recruiting
2
118
US
Difluoromethylornithine, Eflornithine, DFMO
Giselle Sholler
Medulloblastoma
03/28
03/29
NCT04301843: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting
2
131
Canada, US
Eflornithine, DFMO, difluoromethylornithine
Giselle Sholler, K C Pharmaceuticals Inc., Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
10/28
10/33
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
PLAT-02, NCT02028455: A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

Checkmark In ALL at ASCO 2016
Jun 2016 - Jun 2016: In ALL at ASCO 2016
Checkmark Pediatric ALL at ASH 2015
Dec 2015 - Dec 2015: Pediatric ALL at ASH 2015
Checkmark in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
More
Active, not recruiting
1/2
167
US
Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Seattle Children's Hospital
CD19+ Acute Leukemia
08/21
07/36
Snyder, Rachel
NMTT, NCT02679144: Neuroblastoma Maintenance Therapy Trial

Recruiting
2
441
Canada, US
Difluoromethylornithine (DFMO), eflornithine
Giselle Sholler, Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
02/28
02/33
Hall, Susan
NCT05489887: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Recruiting
2
76
Canada, US
Naxitamab, Danyelza, Ceritinib
Giselle Sholler, Y-mAbs
High-risk Neuroblastoma
09/26
09/33
NMTT, NCT02679144: Neuroblastoma Maintenance Therapy Trial

Recruiting
2
441
Canada, US
Difluoromethylornithine (DFMO), eflornithine
Giselle Sholler, Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
02/28
02/33
NCT04696029: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Recruiting
2
118
US
Difluoromethylornithine, Eflornithine, DFMO
Giselle Sholler
Medulloblastoma
03/28
03/29
NCT04301843: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting
2
131
Canada, US
Eflornithine, DFMO, difluoromethylornithine
Giselle Sholler, K C Pharmaceuticals Inc., Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
10/28
10/33
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Completed
1/2
169
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
11/24
12/24
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
NCT05518838: Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

No Longer Available
N/A
US
OKN-007
Oblato, Inc.
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
 
 
NCT04715178: Beat Childhood Cancer Specimen Banking and Data Registry

Recruiting
N/A
500
US
No intervention- registry only
Giselle Sholler
Pediatric Cancer
01/31
01/32
Bielamowicz, Kevin
NCT02875314: HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

Active, not recruiting
4
250
Canada, US, RoW
Induction, vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate, Single Cycle Intensive Chemotherapy, Carboplatin, thiotepa, etoposide, Tandem 3 Cycle Intensive Chemotherapy, Carboplatin, thiotepa
Parth Patel, Children's of Alabama
Medulloblastoma, Central Nervous System Embryonal Tumors
12/25
12/30
NCT05125471: Cobimetinib in Extracranial Arteriovenous Malformations (COBI-AVM Study)

Recruiting
2
17
NA
Cobimetinib, Cotellic
University of Arkansas, Genentech, Inc.
Arteriovenous Malformations (Extracranial)
12/26
12/26
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/24
12/29
NCT05489887: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Recruiting
2
76
Canada, US
Naxitamab, Danyelza, Ceritinib
Giselle Sholler, Y-mAbs
High-risk Neuroblastoma
09/26
09/33
NMTT, NCT02679144: Neuroblastoma Maintenance Therapy Trial

Recruiting
2
441
Canada, US
Difluoromethylornithine (DFMO), eflornithine
Giselle Sholler, Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
02/28
02/33
NCT04696029: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Recruiting
2
118
US
Difluoromethylornithine, Eflornithine, DFMO
Giselle Sholler
Medulloblastoma
03/28
03/29
NCT04301843: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting
2
131
Canada, US
Eflornithine, DFMO, difluoromethylornithine
Giselle Sholler, K C Pharmaceuticals Inc., Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
10/28
10/33
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
NCT04299191: Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

Recruiting
1/2
28
US
LAM561
Laminar Pharmaceuticals, Hackensack Meridian Health, Dana-Farber Cancer Institute, Laminar Pharma Inc
High-grade Glioma, Solid Tumor, Unspecified, Child
06/25
09/25
NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Terminated
1/2
11
Europe, US, RoW
Ponatinib, Chemotherapy Agents
Takeda, Takeda Development Center Americas, Inc.
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
12/23
07/24
NCT05848687: TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II

Recruiting
1/2
90
Canada, US
Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib
Tanja Andrea Gruber, Pediatric Oncology Experimental Therapeutics Investigators' Consortium, Amgen, Lucile Packard Foundation for Children's Health, Kura Oncology, Inc.
Lymphoblastic Leukemia
12/28
12/33
POE14-01, NCT02512926: Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

Completed
1
4
Canada, US
Carfilzomib, Cyclophosphamide, Etoposide
Stanford University, Pediatric Oncology Experimental Therapeutics Investigators' Consortium, Amgen
Relapsed Solid Tumors, Refractory Solid Tumors, Relapsed Leukemia, Refractory Leukemia
08/21
11/23
PARPAML, NCT05101551: Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Recruiting
1
34
US
Talazoparib, Talzenna, Topotecan, Hycamtin, Gemcitabine, Gemzar, Infugem
Norman J. Lacayo, Gateway for Cancer Research
Acute Myeloid Leukemia
03/26
03/26
NCT05518838: Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

No Longer Available
N/A
US
OKN-007
Oblato, Inc.
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
 
 
NCT04715178: Beat Childhood Cancer Specimen Banking and Data Registry

Recruiting
N/A
500
US
No intervention- registry only
Giselle Sholler
Pediatric Cancer
01/31
01/32
Bourgin, Effie
NCT04696029: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Recruiting
2
118
US
Difluoromethylornithine, Eflornithine, DFMO
Giselle Sholler
Medulloblastoma
03/28
03/29
NCT04301843: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting
2
131
Canada, US
Eflornithine, DFMO, difluoromethylornithine
Giselle Sholler, K C Pharmaceuticals Inc., Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
10/28
10/33
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35

Download Options